---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-038414"
form_type: "8-K"
ticker: "ITRMF"
cik: "0001659323"
company_name: "Iterum Therapeutics plc"
filed_at: "2024-03-29T23:59:59+00:00"
generated_at: "2026-06-04T05:23:12.423942+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Iterum Therapeutics posts Q4 net loss $12.4M; NDA resubmission planned early Q2 2024

## Summary
- Net loss of $12.4M for Q4 2023; full year 2023 net loss $38.4M; non-GAAP net loss $10.7M (Q4) and $43.8M (FY).
- Cash, equivalents & short-term investments $23.9M at Dec 31; raised $7.1M post-period via ATM, extending cash runway into 2025.
- NDA resubmission for oral sulopenem in uUTIs on track for early Q2 2024; FDA action expected early Q4 2024 under 6-month review.
- Engaged financial advisor to explore strategic alternatives including a sale or license of sulopenem rights.
- R&D expenses rose to $9.7M (Q4) and $40.0M (FY) driven by the REASSURE trial.

## SEC filing metadata
- accession: 0000950170-24-038414
- form_type: 8-K
- ticker: ITRMF
- cik: 0001659323
- company_name: Iterum Therapeutics plc
- filed_at: 2024-03-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659323/000095017024038414/0000950170-24-038414-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659323/000095017024038414/itrm-20240328.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-038414
- JSON: https://secwatch.observer/filing/0000950170-24-038414.json
- Plain text: https://secwatch.observer/filing/0000950170-24-038414.txt

## Key facts
- Earnings Releases
  Iterum Therapeutics plc reported financial results for the fourth quarter and year ended December 31, 2023.
  - Period: the fourth quarter and year ended December 31, 2023
  - Result: reported results
  source text: On March 28, 2024, Iterum Therapeutics plc issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1659323/000095017024038414/0000950170-24-038414-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.